[Wen, Gebo; Zhong, Jing; Cao, Renxian; Tan, Jingjing; Wu, Ying; Liu, Jianghua; Zu, Xuyu; Zhang, Qinghai] Univ South China, Inst Clin Med, Affiliated Hosp 1, Hengyang 421001, Hunan, Peoples R China.;[Luo, Dixian] First Peoples Hosp Chenzhou, Inst Translat Med, Chenzhou 423000, Hunan, Peoples R China.;[Luo, Dixian] First Peoples Hosp Chenzhou, Dept Lab Med, Chenzhou 423000, Hunan, Peoples R China.;[Cao, Deliang] So Illinois Univ, Sch Med, Simmons Canc Inst, Dept Microbiol Immunol & Cell Biol, Springfield, IL 62794 USA.
[Cao, Renxian] Univ South China, Inst Clin Med, Affiliated Hosp 1, Hengyang 421001, Hunan, Peoples R China.
acetyl-CoA carboxylase;fatty acid biosynthesis;ACC chemical genetics;ACC inhibitors;cancer therapy
Chemical genetic studies on acetyl-CoA carboxylases (ACCs), rate-limiting enzymes in long chain fatty acid biosynthesis, have greatly advanced the understanding of their biochemistry and molecular biology and promoted the use of ACCs as targets for herbicides in agriculture and for development of drugs for diabetes, obesity and cancers. In mammals, ACCs have both biotin carboxylase (BC) and carboxyltransferase (CT) activity, catalyzing carboxylation of acetyl-CoA to malonyl-CoA. Several classes of small chemicals modulate ACC activity, including cellular metabolites, natural compounds, and chemically synthesized products. This article reviews chemical genetic studies of ACCs and the use of ACCs for targeted therapy of cancers.
The Journal of biological chemistry,2011年286(16):13834-13845 ISSN：0021-9258
[Yin, Kai; Zhao, Guo-Jun; Mo, Zhong-Cheng; Cui, Li-Bao; Jiang, Jin; Wen, Ge-Bo; Tang, Chao-Ke; Tan, Chun-Zhi] Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, Life Science Research Center, Hengyang, 421001, China;[Yin, Kai; Wen, Ge-Bo] Department of Diagnostics, Medical College, Hengyang, 421001, China;[Fu, Yuchang] Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL 35294-0012, United States;[Deng, Xiang; Wen, Ge-Bo] Department of Metabolism and Endocrinology, First Affiliated Hospital, University of South China, Hengyang, 421001, China
[Tang, Chao-Ke] Univ S China, Affiliated Hosp 1, Key Lab Atherosclerol Hunan Prov, Life Sci Res Ctr,Inst Cardiovasc Res, Hengyang 421001, Peoples R China.
Transforming growth factor-beta (TGF-beta) is a ubiquitous cytokine playing an essential role in cell proliferation, differentiation, apoptosis, adhesion and invasion, as well as in cellular microenvironment. In malignant diseases, TGF-beta signaling features a growth inhibitory effect at an early stage but aggressive oncogenic activity at the advanced malignant state. Here, we update the current understanding of TGF-beta signaling in cancer development and progression with a focus on breast cancer. We also review the current approaches of TGF-beta signaling-targeted therapeutics for human malignancies.